Skip to main content
4th of July Sale — Get 40% off Vantage subscriptions
Get Started
SubscribeLogin
Published • loading... • Updated

EU Approves Enfortumab Vedotin/Pembrolizumab in Cisplatin-Ineligible MIBC

Summary by cancernetwork.com
Findings from the phase 3 EV-303 trial evaluating the enfortumab-based regimen vs surgery alone in this MIBC group supported the regulatory decision.

2 Articles

Rutland HeraldRutland Herald
Center

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

RAHWAY, N.J.--(BUSINESS WIRE)--Jun 24, 2026-

Read Full Article
cancernetwork.comcancernetwork.com

EU Approves Enfortumab Vedotin/Pembrolizumab in Cisplatin-Ineligible MIBC

Findings from the phase 3 EV-303 trial evaluating the enfortumab-based regimen vs surgery alone in this MIBC group supported the regulatory decision.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
4th of July SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Rutland Herald broke the news on Wednesday, June 24, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

European Union icon

European Union

Rahway icon

Rahway

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal